To test if this VCAM-1-aptamer affects stroke outcomes, we performed tMCAO in a separate cohort of mice and injected VCAM-1-aptamer (0.5 nmol) compared to PBS control (Fig. 2A). The gene discussed is VCAM1; the disease is stroke disorder.